Positive Outlook on Viaskin Peanut Treatment Drives Buy Rating for DBV Technologies

Analyst Jonathan Wolleben from JMP Securities reiterated a Buy rating on DBV Technologies SA – American (DBVT – Research Report) and keeping the price target at $10.00.

Jonathan Wolleben’s rating is based on the promising long-term efficacy and safety of Viaskin Peanut in treating peanut allergies in toddlers. Recent data from the EPOPEX study, an extension of the Phase 3 EPITOPE trial, showed that approximately two-thirds of toddlers could tolerate significantly higher amounts of peanut protein after three years of treatment, providing substantial protection against accidental exposure. Additionally, the treatment demonstrated improved safety, with no serious treatment-related adverse events or anaphylaxis over the course of three years.
DBV Technologies has also provided new analyses indicating that toddlers who adhered to wearing the patch for at least 20 hours a day in the initial phase of treatment showed better clinical responses. This insight could be valuable for guiding real-world application. Furthermore, the alignment with the FDA on patch wear time methodology suggests potential for future regulatory success. These factors collectively contribute to the positive outlook on DBV Technologies and support the Buy rating.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

DBV Technologies SA – American (DBVT) Company Description:

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.